Oct. 2 -- THURSDAY, Oct. 1 (HealthDay News) -- U.S. health officials on Thursday announced new manufacturing standards for the widely used blood-thinner heparin that will decrease the drug's potency ...

Taurolidine is an antibacterial and antifungal agent with a mechanism of action that is less prone to development of antimicrobial resistance. A taurolidine/heparin lock solution carries a lower risk ...

Anticoagulation is an essential component in haemodialysis, which seeks to maintain the delicate balance between preventing clot formation within the extracorporeal circuit and minimising bleeding ...

The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...

The FDA approved a taurolidine and heparin (DefenCath) catheter lock solution for reducing the risk of bloodstream infections in patients on dialysis. Approved under a special limited agency pathway, ...

More than 50 dialysis patients in 12 states have come down with allergic reactions that are being blamed on recalled batches of a blood thinner, federal health officials said Friday. The cases are ...

Heparin-free hemodialysis (HD) is not significantly associated with decreased likelihood of death, bleeding or thrombosis, new findings show. The finding suggests that HD without heparin may be no ...

Hutchison CA and Dasgupta I (2007) National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 22: 1680–1684 The use of heparin to ...

Please provide your email address to receive an email when new articles are posted on . Long-term use of unfractionated heparin may be associated with the loss of lumbar spine bone mineral density in ...

The widow of a man who died after receiving contaminated heparin told a congressional subcommittee Tuesday “we have a false sense of security” in a land where people expect to be protected and safe.

BERKELEY HEIGHTS, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and ...